Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration

Ophthalmology

Volumn 114, Issue 10, 2007, Pages

  Kaiser, Peter K ^a   Blodi, Barbara A ^b   Shapiro, Howard ^c   Acharya, Nisha R ^c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; STATISTICAL SIGNIFICANCE; STEREOSCOPIC VISION; VISUAL ACUITY;

EID: 34748844162     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.04.030     Document Type: Article

References (10)

1. Lopez P.F., Sippy B.D., Lambert H.M., et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37 (1996) 855-868
2. Frank R.N., Amin R.H., Eliott D., et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122 (1996) 393-403
3. Kvanta A., Algvere P.V., Berglin L., and Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37 (1996) 1929-1934
4. Otani A., Takagi H., Oh H., et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 64 (2002) 162-169
5. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
6. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
7. Brown D.M., Kaiser P.K., Michels M., et al. Comparison of ranibizumab and verteporfin photodynamic therapy for neovascular age-related degeneration: 1-year results of the ANCHOR study. N Engl J Med 355 (2006) 1432-1444
8. Chen Y., Wiesmann C., Fuh G., et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293 (1999) 865-881
9. Houck K.A., Leung D.W., Rowland A.M., et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267 (1992) 26031-26037
10. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106